Table 4.
Results of sub-analysis by treatment or DGR for the VEGF-A rs833061 polymorphism and treatment response of nAMD
| FEM or REM* |
Heterogeneity |
||||
|---|---|---|---|---|---|
| No. of cohorts | Genetic model | OR (95% CI) | p (Q) | p (Q) | I2 (%) |
| Sub-analysis by treatment | |||||
| RBZ | C vs T | 1.365 (1.039 to 1.792) | 0.025 | 0.684 | 0.0 |
| CC vs TT | 2.222 (1.252 to 3.944) | 0.001 | 0.992 | 0.0 | |
| CT vs TT | 3.327 (1.709 to 5.590) | 0.000 | 0.878 | 0.0 | |
| CC vs CT+TT | 3.091 (1.025 to 3.661) | 0.000 | 0.965 | 0.0 | |
| CC+CT vs TT | 1.071 (0.731 to 1.568) | 0.726 | 0.678 | 0.0 | |
| RBZ or BVZ | C vs T | 0.778 (0.386 to 1.566) | 0.481 | n.a | n.a |
| CC vs TT | 0.559 (0.121 to 2.587) | 0.457 | n.a | n.a | |
| CT vs TT | 0.690 (0.171 to 2.782) | 0.602 | n.a | n.a | |
| CC vs CT+TT | 0.644 (1.369 to 8.145) | 0.519 | n.a | n.a | |
| CC+CT vs TT | 0.739 (0.249 to 2.190) | 0.585 | n.a | n.a | |
| Sub-analysis by DGR | |||||
| VA | C vs T | 1.307 (0.963 to 1.773) | 0.085 | 0.534 | 0.0 |
| CC vs TT | 2.827 (1.355 to 5.900) | 0.006 | 0.923 | 0.0 | |
| CT vs TT | 3.631 (1.777 to 7.418) | 0.000 | 0.841 | 0.0 | |
| CC vs CT+TT | 3.226 (1.630 to 6.385) | 0.001 | 0.903 | 0.0 | |
| CC+CT vs TT | 0.997 (0.654 to 1.518) | 0.988 | 0.712 | 0.0 | |
| OCT | C vs T | 1.181 (0.751 to 1.857) | 0.472 | 0.122 | 58.2 |
| CC vs TT | 1.463 (0.571 to 3.746) | 0.428 | 0.104 | 62.1 | |
| CT vs TT | 1.446 (0.607 to 3.441) | 0.405 | 0.168 | 47.4 | |
| CC vs CT+TT | 1.458 (0.647 to 3.285) | 0.363 | 0.114 | 59.9 | |
| CC+CT vs TT | 1.125 (0.558 to 2.269) | 0.742 | 0.327 | 0.0 | |
If the p value for Q-statistic was >0.10 or the I2 value was ≥50%, a REM was used, otherwise a FEM was adopted.
BVZ, bevacizumab; DGR, definition of a good response; FEM, fixed-effects model; nAMD, neovascular age-related macular degeneration; OCT, optical coherence tomography; RBZ, ranibizumab; REM, random-effects model; VA, visual acuity; VEGF-A, vascular endothelial growth factor A.